Management Team

Rik J. Deitsch
Chairman and Chief Executive Officer
Nutra Pharma Corporation

Rik J. Deitsch has been the President, Chief Executive Officer and a Director of the Company since November 7, 2002. From February 1998 through November 2002, Mr. Deitsch served as the President of NDA Consulting Inc., a biotechnology research group that provided consulting services to the pharmaceutical industry. NDA Consulting specialized in the research of peptides derived from Cone Snail venom, Cobra venom and Gila Monster venom. Mr. Deitsch holds both a B.S. in Chemistry and an M.S. in Biochemistry from Florida Atlantic University and has conducted clinical and laboratory research in collaboration with scientists at Duke University Medical Center and the Cleveland Clinic . Mr. Deitsch is an adjunct professor and teaches several courses for Florida Atlantic University's College of Business and Continuing Education Department.

Paul F. Reid, PhD.
Chief Executive Officer
ReceptoPharm

Paul F. Reid, PhD. is a Co-Founder of ReceptoPharm. From 1996 to May of 2001, Dr. Reid was an independent consultant to several privately held biotech companies where he used his expertise to assist in corporate development, strategic planning which included writing business plans, estimating market valuations for targeting potential venture capital and corporate partners, and making presentations to U.S. and European financial institutions. Dr. Reid also advised his clients regarding human and veterinary regulatory affairs for the United States, Canada, and Europe, and drug applications (pre IND, IND and Orphan), drug production, new drug development, clinical trial design, patient monitoring, and experimental design.

From 1993 to 1996 Dr. Reid was employed by the United States Medical Research Institute for Infectious Diseases (USMRIID) at Fort Detrick, Maryland, under a grant from the National Research Council in Washington, D.C. Under the grant he was responsible for the expression and purification of a variety of neuroactive components from snake venom in bacterial and yeast systems and purification of expressed material with expansion to large-scale vaccine production. From 1991 to 1993, Dr. Reid was employed as a Post-Doctoral Researcher at Public Health Laboratories in Port Down, England, and Ruhr University in Bochum, Germany, where he was responsible for converting the laboratory to the utilization of genetic techniques. Dr. Reid's Ph.D. studies centered on investigating the activity and function of neural ion channels. Dr. Reid has a Bachelor's Degree in Microbiology from Trinity College in Dublin, Ireland and his Ph.D. is in Neurobiochemistry from Imperial College in London, England. In addition, Dr. Reid has completed FDA courses in current good manufacturing practices (cGMP/cGLP) and the preparation of standard operating procedures (SOPs) in accordance with government guidelines.

Laurence N. Raymond, Ph.D.
Chief Scientific Officer

Laurence N. Raymond, Ph.D. is a Co-Founder of ReceptoPharm. From 1997 to May 2001, Dr. Raymond was a consultant to BioTherapeutics, Inc., also known as Phylomed, Inc., where he was instrumental in the development of monoclonal antibodies utilized in the investigation of modified toxins as well as the development of cell culture, immunochemical and receptor based assays for examination of the therapeutic applications of biopharmaceuticals.

Previously, Dr. Raymond was an Associate Fellow at the Sandoz Research Institute, a division of Sandoz Pharmaceuticals, where he established and managed a laboratory developing monoclonal antibody-based immunoassays. Prior to that Dr. Raymond was Manager of Research and Development for Pel-Freez Biologicals in Rogers, Arkansas, and, simultaneously, Director of the Hybridoma Lab at the University of Arkansas Biotechnology Center in Fayetteville, Arkansas. There he was responsible for establishing and producing monoclonal antibody under contract. Dr. Raymond developed techniques in hybridoma creation and development as well as protein purification and lymphoid stimulation while at the University of New Mexico School of Medicine in Albuquerque. While at the Biophysics Technology Laboratory, at the University of Arizona in Tucson, he developed an adjunct system to plasmaphoresis for the extra-corporal removal of plasma proteins by electrodialysis to be applied to the treatment of Waldenstrom's macroglobulinemia and was applied to the model disease in dogs. He was involved in rheumatoid arthritis research with the Southwestern Clinic and Research Institute in Tucson, Arizona, where he developed his skills in tissue and cell culture, mitogenic and antigenic stimulation of lymphoid cells as well as in-vitro and radio-assays. Dr. Raymond earned a Bachelor's Degree in Nutritional Biochemistry, a Master's of Science Degree in Animal Physiology and a Ph.D. in Microbiology and Immunology all from the University of Arizona.

Harold H. Rumph
Director

Harold H. Rumph has been a director of the Company since March of 2003 and bring with him a career devoted to technical sales and marketing. From 1988 to 2003 he was founder and owner of a high tech business providing computerized scheduling services to the construction industry. From 1986 to 1988, Mr. Rumph was Director of Sales and Marketing for JE Research, Inc. From 1980 to 1986 he was a founder, President, and Director of Biogenix, Inc. This company was involved in the development, manufacturing, and marketing of in-hospital bedside and ambulatory Patient Monitoring Systems. Biogenix was also involved with research and development of antiviral peptides from cobra venoms, including clinical trials under FDA-issued Investigational New Drug applications. Prior to the above Mr. Rumph led sales teams and was responsible for marketing at Harris Communications, Harris Computers, Memorex Corporation, Xerox Corporation, Cincinnati Milacron, Amdahl Corporation, RCA Computers, and IBM. Mr. Rumph received his BS degree from the United States Naval Academy.